2015

August 26th, 2015
,
“The story of this year’s Inc. 5000 is the story of great leadership. In an incredibly competitive business landscape, it takes something extraordinary to take your company to the top”
August 12th, 2015
,
Financial Technology Leader Growing 6,700 Percent
July 20th, 2015
,
Funding From Lighting, Networking and Retail Real Estate Leaders Will Support Global Deployment of Light Sensory Networks
June 3rd, 2015
,
During Day 1 of Coupa INSPIRE’15, the premier cloud spend management industry gathering of the year, Coupa Software disclosed key performance metrics demonstrating its record-breaking customer and business success in Q1 FY2015. In a separate press release, Coupa also announced today the appointment of Todd Ford as the company’s new CFO, effective immediately.
May 27th, 2015
,
NEW YORK--(BUSINESS WIRE)-- CA Technologies (NASDAQ:CA) today announced it has signed a definitive agreement to acquire Rally Software Development Corp. (NYSE:RALY), a leading provider of Agile development software and services, for $19.50 per share, which equates to approximately $480 million, net of cash acquired. The transaction has been unanimously approved by both Boards of Directors, and is expected to close in the second quarter of CA's fiscal 2016. Based in Boulder, CO, Rally has approximately 500 employees across four continents and FY 2015 sales of $88 million.
May 18th, 2015
OpenDNS, a leading provider of cloud-delivered security, today announced that it has opened its enforcement API to customers
April 16th, 2015
,
Leading Professional Services firm deploys Savings-as-a-Service platform
April 13th, 2015
,
HealthTap spearheads the wearable care revolution, enabling you to manage your health and well-being right from your wrist with the new HealthTap App for Apple Watch
April 10th, 2015
,
Emeryville, Calif., April 10, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the Food and Drug Administration (FDA) has granted orphan drug status to ADS-5102 for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease. Adamas currently has multiple Phase 3 studies underway evaluating ADS-5102 for this indication, which currently has no FDA-approved treatment options.